Bloomberg Law
March 17, 2023, 1:45 PM

Sarepta Plunges as Clarity Sought on Muscular Dystrophy Drug (2)

Fiona Rutherford
Fiona Rutherford
Bloomberg News

Sarepta Therapeutics Inc. shares slid the most in two years after the drugmaker disclosed an unexpected regulatory step related its controversial investigative treatment for Duchenne muscular dystrophy.

The US Food and Drug Administration requested an advisory committee meeting about the drug, SRP-9001, that will take place some time before a May 29 regulatory decision date, Sarepta said Thursday in a statement. Shares of Cambridge, Massachusetts-based Sarepta fell as much as 22% at the New York market open on Friday, their biggest intraday loss since January 2021.

The FDA had earlier said it didn’t need the meeting and didn’t give ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.